🇺🇸 FDA
Pipeline program

LVIVO-TaVec400 product

IIT2025143

Phase 1 mab active

Quick answer

LVIVO-TaVec400 product for Multiple Myeloma (MM) is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Multiple Myeloma (MM)
Phase
Phase 1
Modality
mab
Status
active

Clinical trials